Sebastian Grosicki

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové

Publication